isoxazoles has been researched along with Parkinsonian Disorders in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Afify, EA; El-Ganainy, SO; El-Sayed, NS; Gowayed, MA; Matar, NA | 1 |
| Murata, M; Nambu, A; Sano, H | 1 |
| Hirayasu, Y; Odawara, T; Shiozaki, K; Togo, T | 1 |
| Araki, T; Kasahara, J; Kato, H; Kuroiwa, H; Tsukada, T; Uchida, H; Yano, R; Yokoyama, H | 2 |
| Choudhury, ME; Kubo, M; Matsuda, S; Moritoyo, T; Nagai, M; Nishikawa, N; Nomoto, M; Yabe, H | 1 |
| Huang, YC; Liang, CS; Yang, FW | 1 |
7 other study(ies) available for isoxazoles and Parkinsonian Disorders
| Article | Year |
|---|---|
The α7 nAChR allosteric modulator PNU-120596 amends neuroinflammatory and motor consequences of parkinsonism in rats: Role of JAK2/NF-κB/GSk3β/ TNF-α pathway.
Topics: Animals; Dopaminergic Neurons; Glycogen Synthase Kinase 3 beta; Hypokinesia; Isoxazoles; Janus Kinase 2; Neuroinflammatory Diseases; NF-kappa B; Oxidopamine; Parkinsonian Disorders; Phenylurea Compounds; Random Allocation; Rats; Tumor Necrosis Factor-alpha | 2022 |
Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease.
Topics: Animals; Antioxidants; Antiparkinson Agents; Brain; Brain-Derived Neurotrophic Factor; Dopaminergic Neurons; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Nerve Degeneration; Neuroprotective Agents; Parkinsonian Disorders; Zonisamide | 2015 |
Administration of zonisamide in three cases of dementia with Lewy bodies.
Topics: Aged; Antiparkinson Agents; Caregivers; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Isoxazoles; Lewy Body Disease; Middle Aged; Parkinsonian Disorders; Zonisamide | 2010 |
Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Antiparkinson Agents; Disease Models, Animal; Dopamine; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Substantia Nigra; Treatment Outcome; Zonisamide | 2010 |
Zonisamide attenuates MPTP neurotoxicity in marmosets.
Topics: Animals; Antiparkinson Agents; Callithrix; Corpus Striatum; Dopamine; Female; Humans; Isoxazoles; Male; MPTP Poisoning; Neostriatum; Neurons; Neuroprotective Agents; Neurotoxins; Parkinsonian Disorders; Selegiline; Substantia Nigra; Tyrosine 3-Monooxygenase; Zonisamide | 2010 |
Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Antiparkinson Agents; Disease Models, Animal; Dopamine; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neuroprotective Agents; Parkinsonian Disorders; Substantia Nigra; Treatment Outcome; Zonisamide | 2010 |
Rabbit syndrome following discontinuation of paliperidone in a patient with schizoaffective disorder.
Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Parkinsonian Disorders; Psychotic Disorders; Pyrimidines; Substance Withdrawal Syndrome; Syndrome | 2012 |